Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.
In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of sofosbuvir-based treatment compared to current standard treatment in mono-infected patients with chronic hepatitis C (...
Main Authors: | Alena M Pfeil, Oliver Reich, Ines M Guerra, Sandrine Cure, Francesco Negro, Beat Müllhaupt, Daniel Lavanchy, Matthias Schwenkglenks |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4431849?pdf=render |
Similar Items
-
Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions
by: Urs Rusch, et al.
Published: (2019-01-01) -
Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland
by: Philip Bruggmann, et al.
Published: (2015-11-01) -
Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
by: Eiichi Ogawa, et al.
Published: (2020-09-01) -
Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
by: Hyun Phil Shin
Published: (2023-07-01) -
Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
by: Jeong Heo, et al.
Published: (2023-07-01)